|
1
|
Villanueva A: Hepatocellular carcinoma. N
Engl J Med. 380:1450–1462. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Akinyemiju T, Abera S, Ahmed M, Alam N,
Alemayohu MA, Allen C, Al-Raddadi R, Alvis-Guzman N, Amoako Y,
Artaman A, et al: The burden of primary liver cancer and underlying
etiologies From 1990 to 2015 at the global, regional, and national
level: Results from the global burden of disease study 2015. JAMA
Oncol. 3:1683–1691. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Park JW, Chen M, Colombo M, Roberts LR,
Schwartz M, Chen PJ, Kudo M, Johnson P, Wagner S, Orsini LS and
Sherman M: Global patterns of hepatocellular carcinoma management
from diagnosis to death. Liver Int. 35:2155–2166. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kokudo N, Takemura N, Hasegawa K, Takayama
T, Kubo S, Shimada M, Nagano H, Hatano E, Izumi N, Kaneko S, et al:
Clinical practice guidelines for hepatocellular carcinoma: The
Japan society of hepatology 2017 (4th JSH-HCC guidelines) 2019
update. Hepatol Res. 49:1109–1113. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tabrizian P, Jibara G, Shrager B, Schwartz
M and Roayaie S: Recurrence of hepatocellular cancer after
resection: Patterns, treatments, and prognosis. Ann Surg.
261:947–955. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kudo M, Finn RS, Qin S, Han KH, Ikeda K,
Piscaglia F, Baron A, Park JW, Han G, Jassem J, et al: Lenvatinib
versus sorafenib in first-line treatment of patients with
unresectable. Lancet. 391:1163–1173. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S,
Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of
sorafenib in patients in the Asia-pacific region with. Lancet
Oncol. 10:25–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux
M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, et al: Atezolizumab
plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J
Med. 382:1894–1905. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Matsui J, Yamamoto Y, Funahashi Y,
Tsuruoka A, Watanabe T, Wakabayashi T, Uenaka T and Asada M: E7080,
a novel inhibitor that targets multiple kinases, has potent
antitumor activities against stem cell factor producing human small
cell lung cancer H146, based on angiogenesis inhibition. Int J
Cancer. 122:664–671. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ao J, Chiba T, Shibata S, Kurosugi A,
Qiang N, Ma Y, Kan M, Iwanaga T, Sakuma T, Kanzaki H, et al:
Acquisition of mesenchymal-like phenotypes and overproduction of
angiogenic factors in lenvatinib-resistant hepatocellular carcinoma
cells. Biochem Biophys Res Commun. 549:171–178. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Matsuki M, Hoshi T, Yamamoto Y,
Ikemori-Kawada M, Minoshima Y, Funahashi Y and Matsui J: Lenvatinib
inhibits angiogenesis and tumor fibroblast growth factor signaling
pathways in human hepatocellular carcinoma models. Cancer Med.
7:2641–2653. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Myojin Y, Kodama T, Maesaka K, Motooka D,
Sato Y, Tanaka S, Abe Y, Ohkawa K, Mita E, Hayashi Y, et al:
ST6GAL1 is a novel serum biomarker for lenvatinib-susceptible
FGF19-driven hepatocellular carcinoma. Clin Cancer Res.
27:1150–1161. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zheng A, Chevalier N, Calderoni M, Dubuis
G, Dormond O, Ziros PG, Sykiotis GP and Widmann C: CRISPR/Cas9
genome-wide screening identifies KEAP1 as a sorafenib, lenvatinib,
and regorafenib sensitivity gene in hepatocellular carcinoma.
Oncotarget. 10:7058–7070. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fu R, Jiang S, Li J, Chen H and Zhang X:
Activation of the HGF/c-MET axis promotes lenvatinib resistance in
hepatocellular carcinoma cells with high c-MET expression. Med
Oncol. 37:242020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zheng Y, Huang C, Lu L, Yu K, Zhao J, Chen
M, Liu L, Sun Q, Lin Z, Zheng J, et al: STOML2 potentiates
metastasis of hepatocellular carcinoma by promoting PINK1-mediated
mitophagy and regulates sensitivity to lenvatinib. J Hematol Oncol.
14:162021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jin H, Shi Y, Lv Y, Yuan S, Ramirez CFA,
Lieftink C, Wang L, Wang S, Wang C, Dias MH, et al: EGFR activation
limits the response of liver cancer to lenvatinib. Nature.
595:730–734. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vasan N, Baselga J and Hyman DM: A view on
drug resistance in cancer. Nature. 575:299–309. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chatterjee N and Bivona TG: Polytherapy
and targeted cancer drug resistance. Trends Cancer. 5:170–182.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chung CH, Seeley EH, Roder H, Grigorieva
J, Tsypin M, Roder J, Burtness BA, Argiris A, Forastiere AA,
Gilbert J, et al: Detection of tumor epidermal growth factor
receptor pathway dependence by serum mass spectrometry in cancer
patients. Cancer Epidemiol Biomarkers Prev. 19:358–365. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pitteri SJ, Amon LM, Buson TS, Zhang Y,
Johnson MM, Chin A, Kennedy J, Wong CH, Zhang Q, Wang H, et al:
Detection of elevated plasma levels of epidermal growth factor
receptor before breast cancer diagnosis among hormone therapy
users. Cancer Res. 70:8598–8606. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Garrisi VM, Bongarzone I, Mangia A,
Cremona M, De Bortoli M, Vaghi E, Galetta D, Pastorino U, Quaranta
M, Abbate I and Paradiso A: Characterization of a serum protein
pattern from NSCLC patients treated with Gefitinib. Clin Biochem.
44:936–940. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lazzari C, Spreafico A, Bachi A, Roder H,
Floriani I, Garavaglia D, Cattaneo A, Grigorieva J, Viganò MG,
Sorlini C, et al: Changes in plasma mass-spectral profile in course
of treatment of non-small cell lung cancer patients with epidermal
growth factor receptor tyrosine kinase inhibitors. J Thorac Oncol.
7:40–48. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gregorc V, Novello S, Lazzari C, Barni S,
Aieta M, Mencoboni M, Grossi F, De Pas T, de Marinis F, Bearz A, et
al: Predictive value of a proteomic signature in patients with
non-small-cell lung cancer treated with second-line erlotinib or
chemotherapy (PROSE): A biomarker-stratified, randomised phase 3
trial. Lancet Oncol. 15:713–721. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rous P: A sarcoma of the fowl
transmissible by an agent separable from the tumor cells. J Exp
Med. 13:397–411. 1911. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Stehelin D, Varmus HE, Bishop JM and Vogt
PK: DNA related to the transforming gene(s) of avian sarcoma
viruses is present in normal avian DNA. Nature. 260:170–173. 1976.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Czernilofsky AP, Levinson AD, Varmus HE,
Bishop JM, Tischer E and Goodman HM: Nucleotide sequence of an
avian sarcoma virus oncogene (src) and proposed amino acid sequence
for gene product. Nature. 287:198–203. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Luttrell DK, Lee A, Lansing TJ, Crosby RM,
Jung KD, Willard D, Luther M, Rodriguez M, Berman J and Gilmer TM:
Involvement of pp60c-src with two major signaling pathways in human
breast cancer. Proc Natl Acad Sci USA. 91:83–87. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Maa MC, Leu TH, McCarley DJ, Schatzman RC
and Parsons SJ: Potentiation of epidermal growth factor
receptor-mediated oncogenesis by c-Src: Implications for the
etiology of multiple human cancers. Proc Natl Acad Sci USA.
92:6981–6985. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mao W, Irby R, Coppola D, Fu L, Wloch M,
Turner J, Yu H, Garcia R, Jove R and Yeatman TJ: Activation of
c-Src by receptor tyrosine kinases in human colon cancer cells with
high metastatic potential. Oncogene. 15:3083–3090. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
LaVallee TM, Prudovsky IA, McMahon GA, Hu
X and Maciag T: Activation of the MAP kinase pathway by FGF-1
correlates with cell proliferation induction while activation of
the Src pathway correlates with migration. J Cell Biol.
141:1647–1658. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Courtneidge SA, Fumagalli S, Koegl M,
Superti-Furga G and Twamley-Stein GM: The Src family of protein
tyrosine kinases: Regulation and functions. Dev Suppl. 57–64.
1993.PubMed/NCBI
|
|
34
|
Rahimi N, Hung W, Tremblay E, Saulnier R
and Elliott B: c-Src kinase activity is required for hepatocyte
growth factor-induced motility and anchorage-independent growth of
mammary carcinoma cells. J Biol Chem. 273:33714–33721. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Irby RB and Yeatman TJ: Role of Src
expression and activation in human cancer. Oncogene. 19:5636–5642.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhao R, Wu Y, Wang T, Zhang Y, Kong D,
Zhang L, Li X, Wang G, Jin Y, Jin X and Zhang F: Elevated Src
expression associated with hepatocellular carcinoma metastasis in
northern Chinese patients. Oncol Lett. 10:3026–3034. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ito Y, Kawakatsu H, Takeda T, Sakon M,
Nagano H, Sakai T, Miyoshi E, Noda K, Tsujimoto M, Wakasa K, et al:
Activation of c-Src gene product in hepatocellular carcinoma is
highly correlated with the indices of early stage phenotype. J
Hepatol. 35:68–73. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Haas M, Askari A and Xie Z: Involvement of
Src and epidermal growth factor receptor in the signal-transducing
function of Na+/K+-ATPase. J Biol Chem. 275:27832–27837. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yu H and Jove R: The STATs of cancer-new
molecular targets come of age. Nat Rev Cancer. 4:97–105. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yeatman TJ: A renaissance for SRC. Nat Rev
Cancer. 4:470–480. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lau GM, Lau GM, Yu GL, Gelman IH, Gutowski
A, Hangauer D and Fang JW: Expression of Src and FAK in
hepatocellular carcinoma and the effect of Src inhibitors on
hepatocellular carcinoma in vitro. Dig Dis Sci. 54:1465–1475. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yoshida T, Zhang G, Smith MA, Lopez AS,
Bai Y, Li J, Fang B, Koomen J, Rawal B, Fisher KJ, et al: Tyrosine
phosphoproteomics identifies both codrivers and cotargeting
strategies for T790M-related EGFR-TKI resistance in non-small cell
lung cancer. Clin Cancer Res. 20:4059–4074. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Debiais F, Lemonnier J, Hay E, Delannoy P,
Caverzasio J and Marie PJ: Fibroblast growth factor-2 (FGF-2)
increases N-cadherin expression through protein kinase C and
Src-kinase pathways in human calvaria osteoblasts. J Cell Biochem.
81:68–81. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Talpaz M, Shah NP, Kantarjian H, Donato N,
Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E,
et al: Dasatinib in imatinib-resistant Philadelphia
chromosome-positive leukemias. N Engl J Med. 354:2531–2541. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ottmann O, Dombret H, Martinelli G,
Simonsson B, Guilhot F, Larson RA, Rege-Cambrin G, Radich J,
Hochhaus A, Apanovitch AM, et al: Dasatinib induces rapid
hematologic and cytogenetic responses in adult patients with
Philadelphia chromosome positive acute lymphoblastic leukemia with
resistance or intolerance to imatinib: Interim results of a phase 2
study. Blood. 110:2309–2315. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lombardo LJ, Lee FY, Chen P, Norris D,
Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM,
et al: Discovery of N-(2-chloro-6-methyl-
phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)
thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase
inhibitor with potent antitumor activity in preclinical assays. J
Med Chem. 47:6658–6661. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Murakami Y, Sonoda K, Abe H, Watari K,
Kusakabe D, Azuma K, Kawahara A, Akiba J, Oneyama C, Pachter JA, et
al: The activation of SRC family kinases and focal adhesion kinase
with the loss of the amplified, mutated EGFR gene contributes to
the resistance to afatinib, erlotinib and osimertinib in human lung
cancer cells. Oncotarget. 8:70736–70751. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Chang AY and Wang M: Molecular mechanisms
of action and potential biomarkers of growth inhibition of
dasatinib (BMS-354825) on hepatocellular carcinoma cells. BMC
Cancer. 13:2672013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhao H, Lv F, Liang G, Huang X, Wu G,
Zhang W, Yu L, Shi L and Teng Y: FGF19 promotes
epithelial-mesenchymal transition in hepatocellular carcinoma cells
by modulating the GSK3β/β-catenin signaling cascade via FGFR4
activation. Oncotarget. 7:13575–13586. 2016. View Article : Google Scholar : PubMed/NCBI
|
